Evidence map›Paper›PMID 24416337›Full record

ArticlePloS one2014

Sirtuin1 over-expression does not impact retinal vascular and neuronal degeneration in a mouse model of oxygen-induced retinopathy.

Shaday Michan, Aimee M Juan, Christian G Hurst, Zhenghao Cui, Lucy P Evans, Colman J Hatton, Dorothy T Pei, Meihua Ju, David A Sinclair, Lois E H Smith and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. NADProgress in retinal and eye research · 2018
    Review
  9. RORα modulates semaphorin 3E transcription and neurovascular interaction in pathological retinal angiogenesis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Shaday MichanInstituto Nacional de Geriatría, Institutos Nacionales de Salud, México.
Aimee M JuanDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America ; Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Christian G HurstDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Zhenghao CuiDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Lucy P EvansDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Colman J HattonDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Dorothy T PeiDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Meihua JuDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
David A SinclairPaul F. Glenn Laboratories for the Biological Mechanisms of Aging, Department of Genetics, Harvard Medical School, Boston, Massachusetts, United States of America ; Department of Pharmacology, The University of New South Wales, Kensington, Australia.
Lois E H SmithDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Jing ChenDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America ; Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Harvard University · USBoston Children's Hospital · USDana-Farber/Boston Children's Cancer and Blood Disorders Center · USInstituto Nacional de Pediatria · MXUNSW Sydney · AU

Funding

SYNAPTIC MECHANISMS IN HIPPOCAMPAL EPILEPTOGENESISP30HD018655 · NICHD · CHILDREN'S HOSPITAL BOSTON · PI POMEROY, SCOTT LOREN · 1985 to 2015
$26.2M
Dietary control of angiogenesis in retinopathy modelsR01EY017017 · NEI · BOSTON CHILDREN'S HOSPITAL · PI Zhongjie Fu, Lois Smith · 2006 to 2026
$11.8M
Role of Sgs1 DNA helicase in telomere maintenanceR01AG019719 · NIA · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SINCLAIR, DAVID A. · 2001 to 2022
$5.3M
Neuronal guidance molecules control revascularization in retinopathyR01EY022275 · NEI · BOSTON CHILDREN'S HOSPITAL · PI SMITH, LOIS · 2012 to 2014
$1.3M
NEI NIH HHS EY017017NEI NIH HHS EY022275NEI NIH HHS R01 EY017017NEI NIH HHS R01 EY022275NIA NIH HHS R01 AG019719NIA NIH HHS R01AG019719NICHD NIH HHS P01 HD18655NICHD NIH HHS P30 HD018655
6 · The paper itself

Abstract

Proliferative retinopathy is a leading cause of blindness, including retinopathy of prematurity (ROP) in children and diabetic retinopathy in adults. Retinopathy is characterized by an initial phase of vessel loss, leading to tissue ischemia and hypoxia, followed by sight threatening pathologic neovascularization in the second phase. Previously we found that Sirtuin1 (Sirt1), a metabolically dependent protein deacetylase, regulates vascular regeneration in a mouse model of oxygen-induced proliferative retinopathy (OIR), as neuronal depletion of Sirt1 in retina worsens retinopathy. In this study we assessed whether over-expression of Sirtuin1 in retinal neurons and vessels achieved by crossing Sirt1 over-expressing flox mice with Nestin-Cre mice or Tie2-Cre mice, respectively, may protect against retinopathy. We found that over-expression of Sirt1 in Nestin expressing retinal neurons does not impact vaso-obliteration or pathologic neovascularization in OIR, nor does it influence neuronal degeneration in OIR. Similarly, increased expression of Sirt1 in Tie2 expressing vascular endothelial cells and monocytes/macrophages does not protect retinal vessels in OIR. In addition to the genetic approaches, dietary supplement with Sirt1 activators, resveratrol or SRT1720, were fed to wild type mice with OIR. Neither treatment showed significant vaso-protective effects in retinopathy. Together these results indicate that although endogenous Sirt1 is important as a stress-induced protector in retinopathy, over-expression of Sirt1 or treatment with small molecule activators at the examined doses do not provide additional protection against retinopathy in mice. Further studies are needed to examine in depth whether increasing levels of Sirt1 may serve as a potential therapeutic approach to treat or prevent retinopathy.

Indexed as

AnimalsCrosses, GeneticDisease Models, AnimalEndothelial CellsGene ExpressionHeterocyclic Compounds, 4 or More RingsHumansIntegrasesMacrophagesMiceNeovascularization, PathologicNerve DegenerationNestinNeuronsOxygenReceptor, TIE-2Cre recombinaseHeterocyclic Compounds, 4 or More RingsIntegrasesNes protein, mouseNestinOxygenReceptor, TIE-2ResveratrolSirt1 protein, mouseSirtuin 1SRT1720StilbenesTek protein, mouse

Identifiers

PMID24416337
PMCPMC3885684
OpenAlexW2138039127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.